An Automated Standardized System for Managing Adverse Events in Clinical Research Networks Rachel L. RichessonJamie F. MalloyJeffrey P. Krischer Leading Ariticle 03 January 2013 Pages: 807 - 822
Drug-Induced Pancreatitis Anil R. BalaniJames H. Grendell Review Article 03 January 2013 Pages: 823 - 837
Monitoring the Safety of Pioglitazone Rachna KasliwalV. LyndaA. Saad Orginal Research Article 03 January 2013 Pages: 839 - 850
Comparative Risk for Harms of Second Generation Antidepressants Gerald GartlehnerPatricia ThiedaKathleen N. Lohr Orginal Research Article 03 January 2013 Pages: 851 - 865
Spontaneous Adverse Drug Reaction Reporting in Rural Districts of Mozambique Esperança SeveneAlda MarianoXavier Carné Orginal Research Article 03 January 2013 Pages: 867 - 876
Drug-Related Nephrotoxic and Ototoxic Reactions Bertha Maria VerdelEugène P. van PuijenbroekAntoine C. G. Egberts Orginal Research Article 03 January 2013 Pages: 877 - 884
Data Mining in Pharmacovigilance Practice: Which Algorithm to Use? X. YangJ. FreemanR. Bwire Abstract 03 January 2013 Pages: 885 - 885
Post-Authorization Safety Surveillance of a New Pentavalent Vaccine within a National Childhood Vaccination Program in Central America K. HartmannE. AsturiasC. Spyr Abstract 03 January 2013 Pages: 885 - 885
Priority Groups Identification for the Development of Intensified Pharmacovigilance in Bogotá A. Caro Abstract 03 January 2013 Pages: 885 - 885
Searching for Drug-Related Adverse Events in PubMed/MEDLINE Using the MeSH Term “Drug Toxicity” M. O. GarciaF. A. Guzman Abstract 03 January 2013 Pages: 885 - 885
Participation Hospital’s Pharmacist in the Voluntary Reporting Adverse Drug Reactions and Costs Involved in their Management M. KyonenC. CaroG. Muñoz Abstract 03 January 2013 Pages: 885 - 885
Medicinal Product Safety on the UK Market — A Ten Year study A. TangD. LaytonD. Brown Abstract 03 January 2013 Pages: 885 - 885
Sex-Based Comparative Prevalence Study of Drug-Prescribing Factors Increasing the Antipsychotic-Associated Risk of QT-Prolongation/ Torsade-de-Pointe in the Inpatients of a Psychiatric Hospital F. WestphalH. JavelotC. Nonnenmacher Abstract 03 January 2013 Pages: 885 - 885
Do Consumer Reports of Adverse Drug Reactions Add Value or Noise to Postmarketing safety surveillance? S. AhmadL. WestinG. Moses Abstract 03 January 2013 Pages: 885 - 885
International Assessment of Herbal Medicines Pharmacovigilance S. SkaiiiA. KhattabiR. Souiaymani Bencheikh Abstract 03 January 2013 Pages: 885 - 885
A Survey of the Conduct and Reporting of Systematic Reviews Assessing Adverse Effects of Drug Interventions V. CorneliusM. PerrioS. Shakir Abstract 03 January 2013 Pages: 885 - 885
Allergic Reactions to Oral Drugs: A Case/Non Case Study from an Italian Spontaneous Reports Database (GIF) F. SalvoG. PolimeniA. P. Caputi Abstract 03 January 2013 Pages: 885 - 885
Creating Pharmacovigilance Quality Assurance T. CochranS. CurtiU. Prabhakar Abstract 03 January 2013 Pages: 885 - 885
Nimotuzumab Cuban Safety Postmarketing Surveillance P. Piedra SierraG. Saurez MartinezN. Iznaga Escobar Abstract 03 January 2013 Pages: 885 - 885
Safety Profile of Modafinil Used in General Practice in England: A Modified Prescription Event Monitoring study M. DaviesL. WiltonS. Shakir Abstract 03 January 2013 Pages: 885 - 885
Psychoactive Herbs Commercialized in Diadema Streets: Ethnopharmacological Data of an Interdisciplinary Study, Brazil J. Assunção Rodrigues Soares NetoE. Rodrigues Abstract 03 January 2013 Pages: 885 - 885
Novel Approach for Intensive Pharmacovigilance Studies: Application to Hepatitis C Treatment in Mexican Patients R. Jimenez-MendezB. VergaraG. Castaneda-Hernandez Abstract 03 January 2013 Pages: 885 - 885
Psychotropic Drug Used for Attention-Deficit/Hyperactivity Disorder (ADHD) in Italian Children and Adolescent Population P. PaneiA. L. KneiiwoifE. Costabiie Abstract 03 January 2013 Pages: 885 - 885
Profile of Drugs Related to Adverse Event at Brazilian University Hospitals A. M. M. ReisT. C. MarquesS. H. D. R. Cassiani Abstract 03 January 2013 Pages: 885 - 885
Potential Drug-Drug Interactions: An Anti-Microbial Study Using Patients Who Undergo Bone Marrow Transplant S. R. SecoiiR. F. GuastaidiA. M. M. Reis Abstract 03 January 2013 Pages: 885 - 885
Extrapyramidal Side Effects Induced by Trimetazidine K. MasmoudiS. AmesiantM. Andréjak Abstract 03 January 2013 Pages: 885 - 885
Early Post-Marketing Pharmacovigilance of BLASTOFERON®: An Interferon Beta 1a Biosimilar M. KauffmanM. PapouchadoH. Ferro Abstract 03 January 2013 Pages: 885 - 885
Drug Plasma Levels and ADRs: Usefulness of the TDM Plus Algorithm E. Jaquenoud Sirot Abstract 03 January 2013 Pages: 885 - 885
Safety Profile of Extended Release Formulation of Nimesulide in Asian Indian Population: A Prescription Event Monitoring Programme M. SharmaA. ChatterjeeV. B. Gupta Abstract 03 January 2013 Pages: 885 - 885
The Use of Lumiracoxib in General Practice in England: Results of a Modified Prescription-Event Monitoring study D. LaytonV. MarshallS. Shaklr Abstract 03 January 2013 Pages: 885 - 885
Pharmacovigilance Characteristics and Activities within the First Cohort of EU Risk Management Plans (RMPs): Small Molecules vs. Biologicals T. J. GiezenA. K. Mantel-TeeuwisseH. G. M. Leufkens Abstract 03 January 2013 Pages: 885 - 885
Neurological Adverse Side-Effects Induced by Cloxacillin C. MaugardF. MarçonA. Lemaire-Hurtel Abstract 03 January 2013 Pages: 885 - 885
Cutaneous and Corneal Ulcerations Under Nicorandil: A Case Report M. OllagnierC. GuyP. Gain Abstract 03 January 2013 Pages: 885 - 885
Medication Errors Management in Hospital: Three-Month Results L. ThomasC. Cordonnier-JourdinH. Le Louet Abstract 03 January 2013 Pages: 885 - 885
Dermaological Adverse Reactions Associated to Lamotrigine P. MarianiC. SantucciI. Bignone Abstract 03 January 2013 Pages: 885 - 885
The Pharmacovigilance of Vaccines in the National Center of Mexico B. VergaraMd. C. Becerril Abstract 03 January 2013 Pages: 885 - 885
Reports of Serious Adverse Drug Reactions M. R. GruszyckiD. A. AlbaR. M. Osicka Abstract 03 January 2013 Pages: 885 - 885
A Systematic Literature Review of the Determinants of Signal Detection In Post-Marketing Surveillance Systems G. L. FerreiraS. S. ShakirD. Brown Abstract 03 January 2013 Pages: 885 - 885
Improving Spontaneous Reporting of Adverse Drug Reactions: A Trial among Pharmacists I. VazM. T. HerdeiroA. Figueiras Abstract 03 January 2013 Pages: 885 - 885
From Spontaneous Adverse Drug Reporting to Legislation Change of Ketorolac in Taiwan W. ChenC. GauY. Hsieh Abstract 03 January 2013 Pages: 885 - 885
Continuity of Treatment and Data Transmission: A High-Risk Time for Adverse Effects due to Drugs, Especially for Oral Anticoagulant Therapy S. AmesiantC. ChourbagiV. Gras-Champei Abstract 03 January 2013 Pages: 885 - 885
Hypoglycaemia with Pioglitazone: Analysis of data from the Prescription-Event Monitoring (PEM) Study V. VlckovaV. CorneliusS. Shakir Abstract 03 January 2013 Pages: 885 - 885
Association of Cardiovascular Drugs and NOS1AP with QTc Prolongation C. van NoordA. AarnoudseB. Stricker Abstract 03 January 2013 Pages: 885 - 885
Valproic Acid and Hyponatremia A. C. BuireS. MikouT. Trenque Abstract 03 January 2013 Pages: 885 - 885
Analysis of Venous Thromboembolism in the Strontium Ranelate Prescription-Event Monitoring (PEM) Cohort: Interim Results M. PerrioL. WiltonS. Shakir Abstract 03 January 2013 Pages: 885 - 885
From an Identified Risk to Regulatory Measures: Implementation of HLA-B★5701 Screening Before Abacavir Treatment N. CachinC. Kreft-Jais Abstract 03 January 2013 Pages: 885 - 885
Therapeutic Drug Monitoring of Antidementia Drugs: A Valid Tool for Successful Individual Benefit/Risk Evaluation R. KoeberH. H. KluenemannE. Haen Abstract 03 January 2013 Pages: 885 - 885
The Monitoring of Serum Electrolytes and Creatinine in Patients Treated with Antihypertensive Drugs: A Retrospective Analysis in UK General Practice J. J. ColemanS. E. McDowellR. E. Ferner Abstract 03 January 2013 Pages: 885 - 885
Medicines: To Drive or Not to Drive.. Epilogue A. Bénard-LaribièreE. FortF. Haramburu Abstract 03 January 2013 Pages: 885 - 885
Managing Risk between CRO and Sponsor Organisations: The Role of the Contracted Qualified Person for Pharmacovigilance (QPPV) L. Bolitho Abstract 03 January 2013 Pages: 885 - 885